Lazari Capital Management Inc. Has $1.80 Million Holdings in Pfizer Inc. $PFE

Key Points

• Lazari Capital Management Inc. increased its stake in Pfizer Inc. by 19.1% in Q2, owning a total of 74,300 shares valued at approximately $1.80 million.
• Multiple brokerages have adjusted their target prices for Pfizer, with Bank of America raising it to $28.00 and Citigroup to $26.00, reflecting a generally cautious outlook on the stock.
• Pfizer's recent earnings report showed earnings per share of $0.78, exceeding estimates, along with a revenue increase of 10.3% year-over-year.

Lazari Capital Management Inc. boosted its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 19.1% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 74,300 shares of the biopharmaceutical company's stock after purchasing an additional 11,920 shares during the quarter. Pfizer comprises 0.7% of Lazari Capital Management Inc.'s investment portfolio, making the stock its 29th biggest position. Lazari Capital Management Inc.'s holdings in Pfizer were worth $1,801,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of PFE. GKV Capital Management Co. Inc. acquired a new position in Pfizer during the first quarter worth about $27,000. Bayforest Capital Ltd acquired a new position in Pfizer during the first quarter worth about $28,000. North Capital Inc. acquired a new position in Pfizer during the first quarter worth about $28,000. WPG Advisers LLC acquired a new position in Pfizer during the first quarter worth about $35,000. Finally, Horizon Financial Services LLC acquired a new position in Pfizer during the first quarter worth about $35,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on PFE. Bank of America boosted their target price on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Wall Street Zen downgraded Pfizer from a "buy" rating to a "hold" rating in a research note on Sunday. Citigroup upped their price objective on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Finally, Morgan Stanley upped their price objective on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $28.12.

Pfizer Stock Performance

NYSE:PFE opened at $23.75 on Monday. The company has a market capitalization of $135.03 billion, a PE ratio of 12.63, a P/E/G ratio of 0.77 and a beta of 0.55. The company has a 50 day simple moving average of $24.55 and a two-hundred day simple moving average of $24.12. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.